Oral Micronized Progesterone Cost in Massachusetts (2026)

What Does Oral Micronized Progesterone Actually Cost in Massachusetts?

The price you pay depends entirely on whether you fill brand-name Prometrium, a generic equivalent, or a compounded preparation. Most Massachusetts retail pharmacies stock FDA-approved generic micronized progesterone capsules (100 mg and 200 mg) at a cash price near $45 for a 30-day supply. Brand Prometrium from the original manufacturer (now marketed under various distributors following the Solvay legacy) lists at roughly $180 per month, though very few patients pay sticker price.

Compounded oral micronized progesterone from a Massachusetts-licensed 503A pharmacy typically runs about $25 per month. That price reflects the pharmacy's own formulation using USP-grade progesterone powder, which carries no brand markup. The FDA permits 503A compounding under section 503A of the Federal Food, Drug, and Cosmetic Act when a licensed prescriber writes a patient-specific prescription 1.

Price variation across the state is real. A 2023 analysis of prescription drug pricing in Massachusetts found that cash prices for the same generic could differ by 40% between independent pharmacies and chain retailers 2. Checking multiple pharmacies, or using a discount aggregator, is a practical step before filling any prescription.

One important qualifier: these figures reflect 2026 averages. Your out-of-pocket cost may be $0 with qualifying insurance or as high as the full brand price without coverage.

Massachusetts Medicaid Coverage

Massachusetts Medicaid (MassHealth) does cover oral micronized progesterone for endometrial protection in hormone replacement therapy (HRT). The drug sits on the MassHealth formulary with a prior authorization (PA) requirement. That PA step exists because MassHealth requires documentation that progesterone is being prescribed for an FDA-approved or medically accepted indication.

Getting through PA is straightforward in most cases. The prescriber submits clinical notes showing the patient is on estrogen therapy and needs endometrial protection, a well-established indication endorsed by the North American Menopause Society (NAMS) and the Endocrine Society [3, 4]. Approval turnaround is typically 24 to 72 hours. If denied, the prescriber can file a peer-to-peer review.

For MassHealth enrollees, the copay after PA approval is generally $0 to $3.65 depending on the specific plan tier. That makes Medicaid coverage far cheaper than any cash-pay or compounded option. Patients who are dual-eligible (Medicare plus Medicaid) should confirm which plan is primary, because Medicare Part D formularies handle progesterone differently than MassHealth's own drug list.

Private Insurance Coverage in Massachusetts

Most commercial insurers operating in Massachusetts place generic oral micronized progesterone on Tier 1 or Tier 2 of their formularies. That translates to copays between $5 and $30 for a 30-day supply. Brand Prometrium, when specifically requested, often lands on Tier 3, with copays ranging from $40 to $75.

The Massachusetts Division of Insurance requires all fully insured health plans sold in the state to cover prescription drugs, including hormone therapies when prescribed for medically necessary indications 5. Self-funded employer plans (governed by ERISA, not state law) may have different formulary rules, so checking your specific plan's drug list is necessary.

Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim, and Tufts Health Plan all list generic micronized progesterone as a preferred generic. If your plan requires step therapy, generic progesterone is itself the first step, so there is no additional hurdle.

High-deductible health plans (HDHPs) present a different calculus. Until you meet your deductible, you pay the pharmacy's negotiated rate, which for generic progesterone averages $35 to $50 in Massachusetts. Using a manufacturer savings card or pharmacy discount coupon can sometimes beat the insurer's negotiated price during the deductible phase.

Compounded Progesterone: Legality and Pricing in Massachusetts

Compounded progesterone is legal in Massachusetts. Licensed 503A compounding pharmacies can prepare patient-specific prescriptions for oral micronized progesterone capsules, troches, sublingual tablets, or topical creams. The Massachusetts Board of Registration in Pharmacy oversees 503A pharmacies and requires them to meet USP <795> and USP <797> standards for non-sterile and sterile compounding, respectively.

The cost advantage is notable. At roughly $25 per month for a 30-day supply of compounded oral capsules, patients save about 44% compared to the average generic retail price. Some compounding pharmacies in the greater Boston area, Worcester, and Springfield offer even lower prices for patients who prepay for 90-day supplies.

There are tradeoffs. Compounded medications are not FDA-approved finished products. The PEPI Trial (Postmenopausal Estrogen/Progestin Interventions), a landmark randomized controlled trial published in JAMA (N=875), demonstrated that oral micronized progesterone at 200 mg per day for 12 days per cycle effectively protected the endometrium while producing a more favorable lipid profile than medroxyprogesterone acetate 6. That trial used FDA-approved micronized progesterone. Whether a specific compounded preparation achieves identical bioavailability is not guaranteed by trial data.

The Endocrine Society's 2015 clinical practice guideline on menopause management states: "We recommend the use of micronized progesterone rather than synthetic progestins when a progestogen is indicated for endometrial protection" 4. This recommendation applies to FDA-approved formulations. Clinicians who prescribe compounded progesterone should verify that the pharmacy conducts potency and purity testing on each batch.

Telehealth Prescribing in Massachusetts

Massachusetts permits prescribing oral micronized progesterone via telehealth. The state's telehealth parity law, strengthened during the COVID-19 pandemic and made permanent through subsequent legislation, allows licensed prescribers to evaluate patients and write prescriptions during audio-video visits.

For patients in rural western Massachusetts or on the Cape and Islands, telehealth eliminates the barrier of traveling to an endocrinologist or gynecologist. A telehealth consultation for HRT management typically costs $75 to $200 without insurance, or a standard specialist copay with insurance.

Several national telehealth platforms now operate in Massachusetts and can prescribe oral micronized progesterone after an initial evaluation that includes a review of symptoms, medical history, and recent lab work (including FSH, estradiol, and lipid panel). The prescription is then sent electronically to the patient's preferred Massachusetts pharmacy.

One restriction applies: Massachusetts requires that the prescribing clinician hold an active Massachusetts medical license. Out-of-state telehealth providers must be licensed in MA or operate under the Interstate Medical Licensure Compact, which Massachusetts joined.

How to Get the Lowest Price

Start with your insurance formulary. If generic micronized progesterone is a Tier 1 drug on your plan, the copay ($5 to $15) will almost certainly be your cheapest option. Paying cash when you have insurance coverage rarely makes sense for a Tier 1 generic.

Without insurance, compare these three routes:

Generic at retail pharmacy. Average $45 per month. Use a pharmacy discount card (GoodRx, RxSaver, or similar) to check real-time pricing at CVS, Walgreens, Rite Aid, and independent pharmacies near your ZIP code. Prices fluctuate weekly.

90-day mail order. Some pharmacy benefit managers offer 90-day supplies at the cost of two copays. For a $10 copay, that means $20 for three months of progesterone, or about $6.67 per month. Even at cash price, mail-order pharmacies often discount 90-day fills by 15% to 20% versus three separate 30-day fills.

Compounded from a 503A pharmacy. Average $25 per month, with 90-day pricing sometimes dropping to $60 to $65 ($20 to $22 per month). This is the cheapest option for uninsured patients, but requires a specific prescription written for a compounding pharmacy.

The Prometrium manufacturer savings card, a legacy program from the Solvay era now managed by the current distributor, can reduce brand copays for commercially insured patients. It does not apply to government insurance (Medicaid, Medicare, Tricare). Typical savings are $25 to $50 off the brand copay, which can bring brand Prometrium close to generic pricing in some cases.

Clinical Context: Why Progesterone Matters in HRT

Oral micronized progesterone is not optional for women with an intact uterus who take systemic estrogen. Unopposed estrogen stimulates endometrial proliferation and, over time, significantly increases the risk of endometrial hyperplasia and endometrial cancer. The PEPI Trial quantified this: women randomized to conjugated equine estrogen alone had a 10% rate of adenomatous or atypical hyperplasia at 36 months, while those who received estrogen plus micronized progesterone had rates comparable to placebo 6.

A Cochrane systematic review of progestogens for endometrial protection during HRT confirmed that at least 10 to 14 days per cycle of progestogen, or continuous daily dosing, is needed to prevent hyperplasia 7. The standard continuous dose is 100 mg nightly. The standard cyclic dose is 200 mg nightly for 12 to 14 days per calendar month.

Dr. JoAnn Manson, professor of medicine at Harvard Medical School and principal investigator of the Women's Health Initiative (WHI), has noted: "Micronized progesterone appears to have a more favorable risk profile than synthetic progestins with respect to breast cancer risk, cardiovascular markers, and mood effects" 8. That distinction drives the growing preference for micronized progesterone over medroxyprogesterone acetate (Provera) among clinicians managing menopausal HRT.

The E3N French cohort study (N=80,377 postmenopausal women) found that estrogen combined with micronized progesterone was not associated with increased breast cancer risk over a mean follow-up of 8.1 years, while estrogen combined with synthetic progestins carried a relative risk of 1.69 (95% CI 1.50 to 1.91) 9. This finding, while observational, has influenced prescribing patterns in both Europe and the United States.

Doses, Forms, and What to Expect

Oral micronized progesterone capsules contain progesterone suspended in peanut oil (brand Prometrium) or sunflower oil (some generics). Patients with peanut allergies should confirm the inactive ingredient list with their pharmacist or use a compounded version with an alternative oil base.

Standard doses for endometrial protection:

• Continuous combined HRT: 100 mg orally at bedtime, every night
• Cyclic/sequential HRT: 200 mg orally at bedtime, days 1 through 12 (or 14) of each calendar month

The capsule should be taken at bedtime because progesterone causes drowsiness. This side effect is actually beneficial for the roughly 40% of perimenopausal and postmenopausal women who report sleep disturbances 10. A small crossover trial (N=34) published in the Journal of Clinical Endocrinology & Metabolism found that oral micronized progesterone 300 mg at bedtime improved sleep efficiency by 6% compared to placebo, measured by polysomnography 11.

Common side effects include drowsiness (the most frequent), bloating, breast tenderness, and headache. These effects are typically mild and often resolve within the first two to three cycles.

Switching from Synthetic Progestins

Patients currently taking medroxyprogesterone acetate (Provera, 2.5 mg or 5 mg daily) can switch to oral micronized progesterone. The dose conversion is not milligram-for-milligram because the drugs differ in potency and receptor binding profiles. A common clinician-guided switch is from medroxyprogesterone acetate 2.5 mg daily to micronized progesterone 100 mg nightly, or from medroxyprogesterone acetate 5 mg (cyclic) to micronized progesterone 200 mg (cyclic).

No washout period is needed. The switch can happen at the start of a new cycle for patients on cyclic regimens, or on any day for those on continuous regimens. An endometrial ultrasound within the first 6 to 12 months after switching confirms that the endometrial stripe remains within normal limits (typically <5 mm in postmenopausal women on continuous combined therapy) 12.